熱門資訊> 正文
Immunome宣布拟议公开募股
2025-12-16 05:07
- Immunome (NASDAQ:IMNM) announced on Monday its plans to commence an underwritten public offering to issue and sell $400M of shares, and the underwriter will have a 30-day option to purchase up to an additional $60M of shares of its common stock.
- Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC, and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering. Wedbush PacGrow and LifeSci Capital are acting as co-lead managers for the proposed offering.
- The proposed offering is being made pursuant to a shelf registration statement filed with the SEC on February 13, 2024, and automatically became effective upon filing.
More on Immunome
- Seeking Alpha’s Quant Rating on Immunome
- Historical earnings data for Immunome
- Financial information for Immunome
推薦文章
一周財經日曆 | 美聯儲新主席「呼之欲出」！特朗普下周或提前公佈；年末新股上市潮！卧安機器人、英矽智能等6只新股招股中
年終盤點 | 26年投資展望！美股有哪些經濟大事？
年終盤點 | 2025年港美股十大飆升ETF：年內暴漲620%！Palantir多頭槓桿ETF成年度黑馬
年終盤點 | 2025年港股牛股、妖股、熊股名單出爐！這家公司飆升超33倍后跌落神壇
華盛早報 | 科技股強勁反彈！納指一度漲超2%；哈塞特稱仍有很大的降息空間
年終盤點 | 美股七巨頭從「集體狂飆」到「殘酷分化」！誰能在2026年繼續坐莊？
打新攻略 | 2025港股IPO收官戰！6只招股+9只待上市+6只聆訊！打新資金如何巧妙「吃大肉」？
年末貨幣政策「壓軸大戲」：歐洲四央行同日登場，僅一家有望降息？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
